Shilpen Patel
- Oncology top 2%
- Cancer Research top 5%
- Pulmonary and Respiratory Medicine top 10%
- Immunology top 10%
- Molecular Biology
- Co-authors
- Carlos H. BarriosHiroji IwataLuciana MolineroJane Yuet Ching HuiMario Liste-HermosoNadia HarbeckShigehira SajiAnh Nguyen Duc
- Topics
- Cancer Immunotherapy and Biomarkers (6 papers)Advanced Breast Cancer Therapies (5 papers)Breast Cancer Treatment Studies (4 papers)
- Cited by
- OncologyCancer ResearchImmunology
- Partner nations
- United StatesJapanBrazil
In The Last Decade
Shilpen Patel
19 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 68
- Oncology 989
- Cancer Research 422
- Pulmonary and Respiratory Medicine 344
- Immunology 287
- Molecular Biology 219
Countries citing papers authored by Shilpen Patel
This map shows the geographic impact of Shilpen Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shilpen Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shilpen Patel more than expected).
Fields of papers citing papers by Shilpen Patel
This network shows the impact of papers produced by Shilpen Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shilpen Patel. The network helps show where Shilpen Patel may publish in the future.
Co-authorship network of co-authors of Shilpen Patel
This figure shows the co-authorship network connecting the top 25 collaborators of Shilpen Patel. A scholar is included among the top collaborators of Shilpen Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shilpen Patel. Shilpen Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 1 | |
| 4 | 8 | |
| 5 | 15 | |
| 6 | 6 | |
| 7 | 6 | |
| 8 | First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysisbreakdown → | 293 |
| 9 | 1 | |
| 10 | 2 | |
| 11 | 1 | |
| 12 | 44 | |
| 13 | 14 | |
| 14 | Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialbreakdown → | 718 |
| 15 | 60 | |
| 16 | 1 | |
| 17 | 1 | |
| 18 | The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. | 72 |
| 19 | Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. | 15 |
| 20 | 6 |
About Shilpen Patel
Shilpen Patel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology, having authored 20 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Advanced Breast Cancer Therapies (5 papers) and Breast Cancer Treatment Studies (4 papers). The work is most often cited by research in Oncology (989 citations), Cancer Research (422 citations) and Immunology (287 citations). Shilpen Patel has collaborated with scholars based in United States, Japan and Brazil. Frequent co-authors include Carlos H. Barrios, Hiroji Iwata, Luciana Molinero, Jane Yuet Ching Hui, Mario Liste-Hermoso, Nadia Harbeck, Shigehira Saji, Anh Nguyen Duc, Kyung Hae Jung and Roberto Hegg. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.